Ranolazine Stimulates Glucose Oxidation in Normoxic, Ischemic, and Reperfused Ischemic Rat Hearts

McCormack, James G.; Barr, Rick L.; Wolff, Andrew; Lopaschuk, Gary D.

doi:10.1161/01.cir.93.1.135

Cited by 280 publications

(204 citation statements)

References 23 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Leki te nie są jeszcze dostępne w praktyce klinicznej. Lek przeciwdławi-cowy, ranolazyna, hamuje prądy potasowy i sodowy oraz zwiększa metabolizm glukozy kosztem metabolizmu wolnych kwasów tłuszczowych, zwiększając w ten sposób efektywne wykorzystanie tlenu [676,677]. Stosowanie ranolazyny było bezpieczne u pacjentów z zawałem serca bez uniesienia odcinka ST i niestabilną dławicą piersiową ocenianych w badaniu Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome (MERLIN) [678].…”

Section: Nowe Leki Antyarytmiczneunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,401

4,206

View full text Add to dashboard Cite

Section: Nowe Leki Antyarytmiczneunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,401

4,206

View full text Add to dashboard Cite

“…The antianginal compound ranolazine inhibits potassium and sodium currents and increases glucose metabolism at the expense of free fatty acid metabolism, thereby enhancing the efficient use of oxygen. 676,677 Ranolazine was safe in patients with non -ST-segment elevation myocardial infarction and unstable angina evaluated in the MERLIN (Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome) trial. 678 In a post hoc analysis of continuous ECG recordings obtained during the first 7 days after randomization, patients assigned to ranolazine had a trend towards fewer episodes of AF than those on placebo [ Paroxysmal Atrial Fibrillation) trial, the highest tested dose of a combination of ranolazine (750 mg twice daily) and dronedarone (225 mg twice daily) slightly reduced AF burden in 134 subjects with paroxysmal AF and dual-chamber pacemakers.…”

Section: New Antiarrhythmic Drugsmentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof¹,

Benussi²,

Kotecha³

et al. 2016

Eur J Cardiothorac Surg

930

625

View full text Add to dashboard Cite

“…The exact mechanism of action of ranolazine is difficult to elucidate. Firstly, like trimetazidine, ranolazine was shown to promote glucose oxidation, thus improving anaerobic metabolism under ischaemic conditions 61 . Subsequently, ranolazine was shown to cause concentration-dependent, voltage-dependent, and frequency-dependent inhibition of the late sodium current.…”

Section: Ranolazinementioning

confidence: 99%

A 'diamond' approach to personalized treatment of angina

et al. 2017

View full text Add to dashboard Cite

Chronic stable angina pectoris is the most prevalent symptomatic manifestation of ischaemic heart disease, and its management is a priority (BOX 1). Current clinical guidelines recommend antianginal therapy to control symptoms, before considering coronary artery revasculariza tion [1][2][3][4] . However, revascularization by either percutaneous coronary angioplasty or CABG surgery is indicated in patients who have significant artery steno sis (50% left main narrowing or proximal three-vessel disease) to reduce myocardial ischaemia and its adverse clinical manifestation. Antianginal agents are approved by documenting that they improve total exercise duration, together with a reduction in daily frequency of chronic stable angina compared with placebo and/or equivalence to an active comparator. Cardiovascular outcomes, although highly advocated, are not a pre requisite for regulatory approval. None of the antianginal drugs has been proved to reduce cardiovascular mortality or the rate of myocardial infarction. When patients are optimally treated, mortality for chronic stable angina is low, which might explain why all trials designed to improve prognosis have been negative. Guidelines recom mend a first-choice and a second-choice approach, based more on tradition and expert opinion, rather than evidence. This categorical approach has been questioned in the past couple of years 5-8 . Newer antianginal drugs, which are classified as second choice, have more evidence-based clinical data that are more contemporary to support their use than is available for the traditional first-choice drugs. Equally, the often-needed combin ation of double or triple therapy is based on expert opinion and not related to the underlying pathophysio logy. What constitutes optimal antianginal treatment, therefore, varies considerably between countries, and the majority of doctors treat their patients according to their own preconceptions.A group of experts with experience and interest in chronic stable angina met at the University of Ferrara, Italy, to discuss an individualized approach to medical treatment of chronic stable angina, on the basis E X P E RT C O N S E N S U S D O C U M E N TA 'diamond' approach to personalized treatment of angina Abstract | In clinical guidelines, drugs for symptomatic angina are classified as being first choice (β-blockers, calcium-channel blockers, short-acting nitrates) or second choice (ivabradine, nicorandil, ranolazine, trimetazidine), with the recommendation to reserve second-choice medications for patients who have contraindications to first-choice agents, do not tolerate them, or remain symptomatic. No direct comparisons between first-choice and second-choice treatments have demonstrated the superiority of one group of drugs over the other. Meta-analyses show that all antianginal drugs have similar efficacy in reducing symptoms, but provide no evidence for improvement in survival. The newer, second-choice drugs have more evidence-based clinical data that are more contemporary than is available for tr...

show abstract

Ranolazine Stimulates Glucose Oxidation in Normoxic, Ischemic, and Reperfused Ischemic Rat Hearts

Abstract: Beneficial effects of ranolazine in cardiac ischemia/reperfusion may be due, at least in part, to a stimulation of glucose oxidation and a reduction in FA oxidation, allowing improved ATP/O2 and reduction in the buildup of H+, lactate, and harmful fatty acyl intermediates.

Cited by 280 publications

References 23 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

A 'diamond' approach to personalized treatment of angina

Contact Info

Product

Resources

About